Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
RAY903CT
Phase 1 other active
Quick answer
Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial) for Immune-mediated necrotizing myopathy, Antiphospholipid syndrome, Behçet’s Syndrome, Bullous pemphigoid, Dermatomyositis, Immune Thrombocytopenia is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Immune-mediated necrotizing myopathy, Antiphospholipid syndrome, Behçet’s Syndrome, Bullous pemphigoid, Dermatomyositis, Immune Thrombocytopenia
- Phase
- Phase 1
- Modality
- other
- Status
- active